Encyclopedia of Cancer

Living Edition
| Editors: Manfred Schwab


Living reference work entry
DOI: https://doi.org/10.1007/978-3-642-27841-9_1189-4



Cisplatin is classified as a platinum compound and an alkylating cytotoxic agent. Much of our current understanding of the unique properties of platinum drugs has come from studies of cisplatin, especially its antitumor activity. The antitumor activity of platinum (II) complexes requires several unique chemical properties including the presence of chloride, bromide, oxalate, or malonate as leaving group and the neutral complex with inert carrier ligands such as NH3 groups. Minor variations in the structure of these ligands may have a profound effect on the antitumor activity and toxicity of platinum compounds. The cis conformation is required for a complex to be a biologically effective agent and has significant cytotoxic properties, while the transisomer does not.


Since the discovery of the antitumor potential of cisplatin by Rosenberg and coworkers,...


Testicular Cancer Xeroderma Pigmentosum Nonsmall Cell Lung Cancer Cell ERCC1 Expression Human Nonsmall Cell Lung Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.


  1. Barnes KR, Lippard SJ, Barnes KR et al (2004) Cisplatin and related anticancer drugs: recent advances and insights. Met Ions Biol Syst 42:143–177PubMedGoogle Scholar
  2. Matsusaka S, Nagareda T, Yamasaki H et al (2005) Does cisplatin (CDDP) function as a modulator of 5-fluorouracil (5-FU) antitumor action? A study based on a clinical trial. Cancer Chemother Pharmacol 55:387–392CrossRefPubMedGoogle Scholar
  3. McEvoy GK (ed) (2004) AHFS 2004 drug information. American Society of Health-System Pharmacists, Bethesda, pp 929–945Google Scholar
  4. Ueda K, Kawashima H, Ohtani S et al (2006) The 3p21.3 tumor suppressor NPRL2 plays an important role in cisplatin-induced resistance in human non-small-cell lung cancer cells. Cancer Res 66:9682–9690CrossRefPubMedGoogle Scholar
  5. Wang D, Lippard SJ (2005) Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 4:307–320CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  1. 1.Department of Thoracic & Cardiovascular SurgeryThe University of Texas M.D. Anderson Cancer CenterHoustonUSA